Previous 10 | Next 10 |
Invitae Receives Notice of Non-Compliance with NYSE Minimum Share Price Continued Listing Standard PR Newswire SAN FRANCISCO , Sept. 22, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that it received a noti...
2023-09-21 05:00:00 ET Fool.com contributor Parkev Tatevosian considers Invitae (NYSE: NVTA) stock and its financial prospects to determine if investors should buy the stock. *Stock prices used were the afternoon prices of Sept. 18, 2023. The video was published on Sept. 20, 2...
2023-09-19 05:30:00 ET It's best not to go all in on high-risk stocks, but that doesn't mean you should avoid them entirely. If you can tolerate some risk, certain players could make a good addition to a diversified portfolio. That's because, along with the risk, these companies also of...
2023-09-14 14:00:00 ET Since December 2021, superstar investor Cathie Wood has been adding to her position in genetic-testing company Invitae (NYSE: NVTA) while many investors were doing just the opposite. The stock has declined more than 90% since that time. Wood's latest Invitae t...
Invitae Hires Industry Veteran Robert Guigley as Chief Commercial Officer PR Newswire – Invitae adds chief commercial officer to leadership team; Innovative leader to help expand market share and drive revenue growth – SAN FRANCISCO , Aug. 28 , 20...
2023-08-24 10:00:34 ET Gainers: CollPlant Biotechnologies ( CLGN ) +11% NeuBase Therapeutics ( NBSE ) +7% NeuroPace ( NPCE ) +7% Bionomics ( BNOX ) +6% Enhabit ( EHAB ) +16% Losers: NanoVibronix ( NAOV ) -15% ...
Clinical Trial Results Support Genetic Testing of All Patients with Prostate Cancer PR Newswire – Research published in European Urology Oncology shows restrictive genetic testing criteria miss a significant number of prostate cancer patients with potentially actionable i...
2023-08-14 17:06:08 ET More on Invitae Invitae: Revenue Troubles Build Invitae Corporation ( NVTA ) Q2 2023 Earnings Call Transcript Invitae Corporation 2023 Q2 - Results - Earnings Call Presentation Invitae Is Treading In Competitive Waters Invit...
Invitae Announces Selection of Finance Executive Robert Dickey as Interim CFO PR Newswire – Christine Gorjanc resumes role as Chair of the Audit Committee of the Board of Directors for Invitae – SAN FRANCISCO , Aug. 14, 2023 /PRNewswire/ -- ...
2023-08-11 08:00:00 ET Fool.com contributor Parkev Tatevosian offers investors an earnings review of Invitae (NYSE: NVTA) and lets you know if the beaten-down growth stock is a buy. *Stock prices used were the afternoon prices of Aug. 8, 2023. The video was published on Aug. 1...
News, Short Squeeze, Breakout and More Instantly...
Labcorp Announces Winning Bid for Select Assets of Invitae PR Newswire Advances Labcorp strategy to launch and scale specialty testing in areas such as oncology and rare diseases Transaction requires court approval, with confirmation expected on May 6, 2024 ...
Invitae Enters into Agreement with Labcorp for Sale of Business PR Newswire – Labcorp Selected as Winning Bidder in Court-Supervised Sale Process, Subject to Court and Regulatory Approvals – – $239 Million Cash Bid Includes Acquisition of Substantial...
Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance PR Newswire – Study findings to be presented at the 2024 American Society of Breast Surgeons Annual Meeting – SAN FRANCISCO , April 11, 2024 /PRNewsw...